Emerging glaucoma treatments: are we seeing an improvement in adherence?

IF 0.9 Q4 OPHTHALMOLOGY
Expert Review of Ophthalmology Pub Date : 2023-01-01 Epub Date: 2023-04-12 DOI:10.1080/17469899.2023.2199981
Andrew P Droste, Paula Anne Newman-Casey
{"title":"Emerging glaucoma treatments: are we seeing an improvement in adherence?","authors":"Andrew P Droste, Paula Anne Newman-Casey","doi":"10.1080/17469899.2023.2199981","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Non-adherence to glaucoma medication and poor follow-up is a global health concern.</p><p><strong>Areas covered: </strong>Glaucoma remains one of the largest causes of irreversible blindness worldwide. Traditional treatment guidelines suggest topical eye drop medication as first line therapy followed by addition of supplementary medications before proceeding to more invasive glaucoma surgeries. Unfortunately, poor glaucoma self-management remains high, leading to disease progression and blindness. Recent advancements in the field of pharmacotherapies, surgeries, and behavioral approaches have taken aim at increasing support for glaucoma self-management. We review the current and emerging approaches towards glaucoma management, with the exception of bleb-based surgical approaches, to investigate if they have had an impact on adherence. Literature searches were conducted via MEDLINE (PubMed), Embase (Elsevier), Cochrane Library (Wiley), and Preprints from January 1<sup>st</sup>, 2018, to January 26th, 2023.</p><p><strong>Expert opinion: </strong>The ability to offer patients a multitude of choices enables patients to tailor their glaucoma treatment to their values and lifestyle. Offering personalized patient education and coaching to support chronic glaucoma self-management would better enable patient engagement in whichever treatment path is chosen. Currently, literature regarding the impact of these new advancements on treatment engagement is lacking; this field is ripe for additional intervention and assessment.</p>","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373909/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17469899.2023.2199981","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Non-adherence to glaucoma medication and poor follow-up is a global health concern.

Areas covered: Glaucoma remains one of the largest causes of irreversible blindness worldwide. Traditional treatment guidelines suggest topical eye drop medication as first line therapy followed by addition of supplementary medications before proceeding to more invasive glaucoma surgeries. Unfortunately, poor glaucoma self-management remains high, leading to disease progression and blindness. Recent advancements in the field of pharmacotherapies, surgeries, and behavioral approaches have taken aim at increasing support for glaucoma self-management. We review the current and emerging approaches towards glaucoma management, with the exception of bleb-based surgical approaches, to investigate if they have had an impact on adherence. Literature searches were conducted via MEDLINE (PubMed), Embase (Elsevier), Cochrane Library (Wiley), and Preprints from January 1st, 2018, to January 26th, 2023.

Expert opinion: The ability to offer patients a multitude of choices enables patients to tailor their glaucoma treatment to their values and lifestyle. Offering personalized patient education and coaching to support chronic glaucoma self-management would better enable patient engagement in whichever treatment path is chosen. Currently, literature regarding the impact of these new advancements on treatment engagement is lacking; this field is ripe for additional intervention and assessment.

新兴的青光眼治疗方法:我们是否看到依从性有所改善?
导言:不坚持青光眼药物治疗和随访不力是一个全球性的健康问题:青光眼仍然是导致全球不可逆转性失明的最大原因之一。传统的治疗指南建议将局部滴眼液作为一线疗法,然后在进行更具侵入性的青光眼手术之前添加辅助药物。遗憾的是,青光眼患者的自我管理能力仍然很差,导致病情恶化和失明。药物治疗、手术和行为疗法领域的最新进展旨在加强对青光眼自我管理的支持。我们回顾了当前和新出现的青光眼管理方法(除基于眼泡的手术方法外),以研究这些方法是否对坚持治疗青光眼有影响。从2018年1月1日至2023年1月26日,我们通过MEDLINE(PubMed)、Embase(Elsevier)、Cochrane Library(Wiley)和Preprints进行了文献检索:为患者提供多种选择的能力使患者能够根据自己的价值观和生活方式定制青光眼治疗方案。提供个性化的患者教育和指导以支持慢性青光眼的自我管理,将更好地帮助患者参与所选择的治疗途径。目前,有关这些新进展对治疗参与度影响的文献还很缺乏;这一领域的干预和评估时机已经成熟。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Ophthalmology
Expert Review of Ophthalmology Health Professions-Optometry
CiteScore
1.40
自引率
0.00%
发文量
39
期刊介绍: The worldwide problem of visual impairment is set to increase, as we are seeing increased longevity in developed countries. This will produce a crisis in vision care unless concerted action is taken. The substantial value that ophthalmic interventions confer to patients with eye diseases has led to intense research efforts in this area in recent years, with corresponding improvements in treatment, ophthalmic instrumentation and surgical techniques. As a result, the future for ophthalmology holds great promise as further exciting and innovative developments unfold.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信